TENAYA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.31 USD | +2.13% |
|
-0.23% | +33.02% |
| Mar. 20 | Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating | MT |
| Mar. 19 | North American Morning Briefing : Stock Futures -2- | DJ |
Chart calendar Tenaya Therapeutics, Inc.
38024f4a7c6448.bT86CA_Q4WS80t0sOKzRCQcR0xXeszp21bcO4adFTPQ.LExicXiXtDvkq48besqaYnBZll206U4lpv48ptUsP7wEbVJ9X7y2LNqoug~758e38e931e09384f97f5e3169a36a4f
Upcoming events on Tenaya Therapeutics, Inc.
Past events on Tenaya Therapeutics, Inc.
| 2024-03-18 04:05 pm | Q4 2023 Earnings Release |
| 2024-03-12 10:40 am | Leerink Partners Global Biopharma Conference |
| 2024-03-05 02:10 pm | TD Cowen Health Care Conference - Panel |
| 2024-01-11 12:45 pm | JPMorgan Healthcare Conference |
| 2023-11-28 09:30 am | Piper Sandler Healthcare Conference |
| 2023-11-08 04:05 pm | Q3 2023 Earnings Release |
| 2023-10-12 12:00 am | Cell & Gene Meeting on the Mesa Conference |
| 2023-10-08 12:45 pm | Heart Failure Society Scientific Meeting - ePoster No: 417 |
| 2023-10-07 08:00 am | Heart Failure Society Scientific Meeting - ePoster No: 104 |
| 2023-10-06 01:00 pm | Hypertrophic Cardiomyopathy Medical Society Scientific Meeting |
| 2023-10-05 | Heart Failure Society Scientific Meeting |
| 2023-09-12 02:55 pm | Morgan Stanley Global Healthcare Conference |
| 2023-08-09 04:05 pm | Q2 2023 Earnings Release |
| 2023-08-09 11:00 am | Canaccord Genuity Growth Conference |
| 2023-06-08 11:00 am | Annual General Meeting |
| 2023-05-18 03:00 pm | American Society of Gene Cell Therapy Meeting - Abstract No: #1113 |
| 2023-05-18 03:00 pm | American Society of Gene Cell Therapy Meeting - Abstract No: #1010 |
| 2023-05-17 03:00 pm | American Society of Gene Cell Therapy Meeting - Abstract No: #463 |
| 2023-05-17 03:00 pm | American Society of Gene Cell Therapy Meeting - Abstract No : #409 |
| 2023-05-15 | American Society of Gene Cell Therapy Meeting - Abstract No: #407 |
Annual results
| Fiscal Period | December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,83 |
|
EBITDA Million USD | Released Forecast Spread | -66,9 -53,0 -26.32% | -119 -116 -3.14% | -123 -124 1.31% | -142 |
|
EBIT Million USD | Released Forecast Spread | -72,8 -63,8 -14.08% | -126 -119 -5.22% | -131 -129 -1.43% | -139 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -72,7 -67,6 -7.57% | -124 -120 -3.17% | -124 -125 1% | -133 |
|
Net income Million USD | Released Forecast Spread | -72,7 -67,6 -7.57% | -124 -120 -3.17% | -124 -126 1.89% | -136 |
|
EPS USD | Released Forecast Spread | -4,10 -9,95 58.79% | -2,76 -2,71 -1.69% | -1,68 -1,72 2.08% | -1,73 |
| Announcement Date | 23/03/22 | 08/03/23 | 18/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,83 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -28,6 -32,2 11.12% | -29,2 -30,3 3.59% | -32,4 -31,7 -2.31% | -31,6 -36,0 12.24% | -35,1 -38,1 7.86% | -28,7 -39,0 26.31% | -29,3 -33,1 11.59% | -32,8 | -34,3 | -36,5 | -33,4 | |||
|
EBIT Million USD | Released Forecast Spread | -26,2 -21,1 -24.11% | -31,2 -27,3 -13.98% | -28,6 -33,2 13.81% | -31,3 -25,4 -23.02% | -34,6 -29,3 -17.97% | -33,7 -37,0 8.8% | -35,1 -36,1 2.67% | -30,9 -34,8 11.2% | -31,4 -31,4 -0.15% | -32,1 | -33,4 | -35,4 | -39,0 | -40,9 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -26,2 -21,0 -24.4% | -31,1 -27,3 -13.82% | -28,4 -32,8 13.52% | -30,7 -25,7 -19.55% | -33,5 -29,8 -12.39% | -31,7 -36,9 13.94% | -33,3 -35,9 7.44% | -29,1 -35,2 17.18% | -29,9 -31,2 3.97% | -32,1 | -33,5 | -35,6 | -36,9 | -40,9 |
|
Net income Million USD | Released Forecast Spread | -26,2 -21,0 -24.4% | -31,1 -27,3 -13.82% | -28,4 -32,8 13.52% | -30,7 -25,7 -19.55% | -33,5 -29,8 -12.39% | -31,7 -36,9 13.94% | -33,3 -35,9 7.44% | -29,1 -35,2 17.18% | -29,9 -32,3 7.37% | -33,4 | -34,4 | -36,0 | -37,0 | -40,9 |
|
EPS USD | Released Forecast Spread | -0,63 -0,78 19.23% | -0,75 -0,67 -11.94% | -0,69 -0,76 8.97% | -0,74 -0,63 -17.83% | -0,61 -0,64 4.09% | -0,43 -0,59 26.5% | -0,45 -0,50 9.27% | -0,39 -0,48 19.03% | -0,40 -0,44 8.5% | -0,42 | -0,43 | -0,44 | -0,45 | -0,54 |
| Announcement Date | 23/03/22 | 11/05/22 | 10/08/22 | 10/11/22 | 08/03/23 | 10/05/23 | 09/08/23 | 08/11/23 | 18/03/24 | - | - | - | - | - |
| Today 04:05 pm | QIAGEN N.V.: Q1 2024 Earnings Release |
| 2024-04-29 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 2024-05-01 06:30 am | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 2024-05-01 06:30 am | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 2024-05-01 07:00 am | ALKERMES PLC: Q1 2024 Earnings Release |
| 2024-05-01 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for Tenaya Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- TNYA Stock
- Calendar Tenaya Therapeutics, Inc.
